Cameron Turtle, Spyre Therapeutics CEO
December 8, 2023 07:12 AM ESTUpdated 07:26 AM
Financing

Fresh from re­brand, Spyre Ther­a­peu­tics rais­es $180M as it steers TLA1 pro­gram to clin­ic

Katherine Lewin

News Reporter

Spyre Ther­a­peu­tics is pulling in $180 mil­lion in a pri­vate place­ment just a cou­ple of weeks af­ter it re­brand­ed from Ae­glea …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

IGM Bio­sciences’ au­toim­mune piv­ot lasts three months af­ter in­ter­im da­ta dis­ap­point

Shore­line cuts staff as its part­ner­ship with Gilead­'s Kite is now in flux

Ver­sant un­veils Light Horse with $62M and a part­ner­ship with No­var­tis

Aio­los team re­unites with $411M for new biotech with obe­si­ty drugs from Chi­na

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Cell ther­a­py start­up A2 Bio­ther­a­peu­tics nets $80M Se­ries C

A service from the Financial Times